<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01204554</url>
  </required_header>
  <id_info>
    <org_study_id>08/223b.2008/3837 (REK)</org_study_id>
    <nct_id>NCT01204554</nct_id>
  </id_info>
  <brief_title>Microcirculation in Perforator Flaps. Enhancing Tissue Survival</brief_title>
  <official_title>Microcirculation in Perforator Flaps. Enhancing Tissue Survival</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to assess the microcirculatory changes in the distal part of
      the perforator flap using ICG fluorescence angiography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perforator flaps are increasingly used in reconstructive surgery both as pedicled and free
      flaps, mostly because of reduced donor site morbidity and superior aesthetic result. However,
      the there is still much to learn about the hemodynamic changes within these flaps.The aim of
      the present study is to assess the microcirculatory changes in the distal part of the
      perforator flap using ICG fluorescence angiography.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean pixel intensity using dynamic laser-induced-fluorescence-videoangiography</measure>
    <time_frame>dec. 2008--des 2010</time_frame>
    <description>Perfusion measurements were conducted intraoperatively by assessing microcirculation using the technique of dynamic laser-induced-fluorescence-videoangiography (IC-VIEW, PULSION Medical Systems AG, Munich, Germany).</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Reconstructive Surgery</condition>
  <condition>Microcirculation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine green (ICG)</intervention_name>
    <description>a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients submitted to elective abdominoplasty

        Exclusion Criteria:

          -  body mass index &lt; 30 kg/m2

          -  morbidly obese

          -  patients with comorbidity such as diabetes

          -  vascular disease

          -  smokers

          -  patients &lt; 18 years, and patients using anti-coagulant therapy

          -  pregnant

          -  severe hepatic insufficiency were excluded and a history of allergic reactions to ICG
             and iodide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haris Mesic, M.D</last_name>
    <phone>004722118080</phone>
    <email>Haris.Mesic@oslo-universitetssykehus.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0304</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haris Mesic, M.D</last_name>
      <phone>004722118080</phone>
      <email>haris.mesic@oslo-universitetssykehus.no</email>
    </contact>
    <investigator>
      <last_name>Haris Mesic, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravi Bains, MD. PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2010</study_first_submitted>
  <study_first_submitted_qc>September 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2010</study_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Haris Mesic</name_title>
    <organization>Oslo University Hospital</organization>
  </responsible_party>
  <keyword>perforator flaps</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

